It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Safeguards against excess DNA replication are often dysregulated in cancer, and driving cancer cells towards over-replication is a promising therapeutic strategy. We determined DNA synthesis patterns in cancer cells undergoing partial genome re-replication due to perturbed regulatory interactions (re-replicating cells). These cells exhibited slow replication, increased frequency of replication initiation events, and a skewed initiation pattern that preferentially reactivated early-replicating origins. Unlike in cells exposed to replication stress, which activated a novel group of hitherto unutilized (dormant) replication origins, the preferred re-replicating origins arose from the same pool of potential origins as those activated during normal growth. Mechanistically, the skewed initiation pattern reflected a disproportionate distribution of pre-replication complexes on distinct regions of licensed chromatin prior to replication. This distinct pattern suggests that circumventing the strong inhibitory interactions that normally prevent excess DNA synthesis can occur via at least two pathways, each activating a distinct set of replication origins.
DNA replication processes are often dysregulated in cancer. Here the authors analyse DNA synthesis patterns in cancer cells undergoing partial genome re-replication to reveal that re-replication exhibits aberrant replication fork dynamics and a skewed distribution of replication initiation that over-duplicates early-replicating genomic regions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129)
2 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Kanazawa Medical University, Department of Microbiology, Kanazawa, Japan (GRID:grid.411998.c) (ISNI:0000 0001 0265 5359)
3 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Chungbuk National University, Department of Biochemistry, Cheongju, Korea (GRID:grid.254229.a) (ISNI:0000 0000 9611 0917)
4 Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129); Oregon Health and Science University, Program in Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690)